First U.S. Patients Receive Agili-C™ Implants
NEW ORLEANS, Louisiana and KFAR SABA, Israel, August 23, 2018
NEW ORLEANS, Louisiana and KFAR SABA, Israel, August 23, 2018 /PRNewswire/ --
CartiHeal, developer of Agili-C, a proprietary implant for the treatment of joint surface lesions, and two LSU Health New Orleans orthopaedic surgeons announced today the successful enrollment of the first two U.S. patients in the Agili-C IDE pivotal study. The first two cases in the United States were performed by Principle Investigator Dr. Vinod Dasa, Associate Professor and Director of Orthopaedic Research, and Dr. Michael Hartman, Associate Professor of Orthopaedic Surgery at LSU Health New Orleans School of Medicine, on August 14, 2018.
The first patient who was randomized to receive an Agili-C implant in the U.S. is a 53-year-old male. He suffered from a chronic painful cartilage lesion in the trochlea's center and received a single implant in a mini-arthrotomy approach.
"Currently we lack good treatment options for patients who experience persistent knee pain due to cartilage problems and are too young for knee replacement," said Dr. Dasa. "The Agili-C implantation was smooth without complications. We plan to enroll more patients in the upcoming weeks and hope that this lDE trial finds that the Agili-C implant alleviates pain in these patients, allowing them to return to an active lifestyle."
In Europe and Israel, 80 patients have already been enrolled and treated in the study, which will include a minimum of 250 patients in U.S. and OUS centers, aiming for an FDA PMA application. The trial's objective is to demonstrate the superiority of the Agili-C implant over surgical standard of care (microfracture and debridement) for the treatment of cartilage or osteochondral defects, in both arthritic knees and knees without degenerative changes.
Nir Altschuler, Cartiheal's founder & CEO, said, "We would like to congratulate Dr. Dasa and Dr. Hartman for enrolling the first two US patients. This is a significant milestone for our company and for our study. We are very pleased with the enrollment rate to date, and plan to open more U.S. sites in the near future."
CartiHeal's cell-free, off-the-shelf implant is CE marked for use in cartilage and osteochondral defects. Agili-C was implanted in a series of trials conducted in leading centers in Europe and Israel, in over 400 patients with cartilage lesions in the knee, ankle and great toe. In these trials, the implant was used to treat a broad spectrum of cartilage lesions, from single focal lesions to multiple and large defects in patients suffering from osteoarthritis.
For more information about the Agili-C IDE study at LSU Health New Orleans, contact Cara Rowe, MSW, CCRP, Orthopaedics Clinical Research Coordinator at 504-568-4640.
CartiHeal, a privately-held medical device company with headquarters in Israel, develops proprietary implants for the treatment of cartilage and osteochondral defects in traumatic and osteoarthritic joints. In the United States the Agili-C implant is not available for sale - it is an investigational device limited for use in the IDE study.
LSU Health Sciences Center New Orleans educates Louisiana's health care professionals. The state's flagship and most comprehensive health sciences university, LSU Health New Orleans includes a School of Medicine, the state's only School of Dentistry, Louisiana's only public School of Public Health, and Schools of Allied Health Professions, Nursing, and Graduate Studies. LSU Health New Orleans faculty take care of patients in public and private hospitals and clinics throughout the region. In the vanguard of biosciences research in a number of areas in a worldwide arena, the LSU Health New Orleans research enterprise generates jobs and enormous economic impact. LSU Health New Orleans faculty have made lifesaving discoveries and continue to work to prevent, advance treatment, or cure disease. To learn more, visit http://www.lsuhsc.edu , http://www.twitter.com/LSUHealthNO, or http://www.facebook.com/LSUHSC .